New Dual-Action Drug Structure Could Transform Cancer and Autoimmune Disease Treatment

Scientists at Perm National Research Polytechnic University (PNRPU) have created a new molecular structure for drugs that could revolutionize cancer and autoimmune disease treatment. The breakthrough allows a single compound to combat tumors while also reducing inflammation. This dual-action approach aims to enhance effectiveness and decrease harmful side effects.

The research builds on aspirin's chemical properties but introduces a key modification using urea. By synthesizing novel compounds, the team developed molecules with both anti-cancer and anti-inflammatory effects. However, early versions faced a major challenge: structural instability.

The PNRPU team overcame this by designing a method for self-assembly. This process locks the molecules into a rigid, stable shape. A critical step came during cyclization, where a linear molecule was converted into a closed ring. The technique achieved a 68% yield, providing the stability needed for further development.

The resulting framework could combine pain relief, inflammation control, and disease suppression in one drug. While promising, no clinical trials for this technology have yet been registered in public databases like ClinicalTrials.gov or the WHO ICTRP as of February 2026.

This innovation opens avenues for more efficient treatments in oncology and severe autoimmune conditions. The next step will depend on further testing and eventual clinical trials. Until then, the technology remains in the research phase, with no confirmed timeline for patient use.